摘要
尽管近年来联合化疗的应用使得成人急性髓系白血病(AML)的治疗取得了长足进步,但总体长期生存率仍然不高,主要原因是复发率高和化疗耐药的影响。复发难治性AML再治疗化疗方案强烈,由于化疗药物缺乏对肿瘤细胞特异性的识别,往往产生显著的不良反应而危及患者生命。为改善患者生活质量及生存率,迫切需要新的治疗策略。随着科学研究的深入,不断有肿瘤细胞分子新靶点包括细胞表面分子异常表达、基因突变和基因异常甲基化等被发现。针对上述异常改变的靶向药物的出现,改善了AML患者的预后,为AML治疗提供了新的途径。本文仅就AML分子靶向治疗最新研究进展做一简述。
Although the application of combined chemotherapy has made a great progress in treatment of adult acute myeloid leukemia（ AML）,the overall survival rate is still not high,mainly because of high recurrence rate and drug resistance. The treatment regimen for relapsed/refractory AML is always strong. Due to the chemotherapy drugs lacking of specific identification of tumor cells,significant adverse reactions often come out and sometimes even endanger the life of patients. In order to improve the life quality and survival rate,the new treatment strategy is urgently needed. With the deepening of research,the new molecular targets of tumor cells including the abnormal expression of cell surface morecules,gene mutation and abnormal gene methylation has been found. Targeted drugs for these abnormal changes could improve the prognosis of AML patients,providing a new way for AML treatment. This review summarizas the progress of molecular targeted therapy of AML.
作者
田晨
李越洋
胡冬至
TIAN Chen;LI Yue-Yang;HU Dong-Zhi(Department of Hematology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin 300060,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2018年第4期1253-1256,共4页
Journal of Experimental Hematology
基金
国家自然科学基金(81670104
81570201)
